Dr. Suzanne Dawn Turner
Specialist, Institute of Medical Genetics and Genomics
| e‑mail: |
|---|
Total number of publications: 39
2025
-
Aiming Towards a Chemotherapy-Minimal Regimen for Paediatric Anaplastic Large Cell Lymphoma Using Combination Therapies Involving ALK Inhibitors
Year: 2025, type: Conference abstract
-
Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome
Redox Biology, year: 2025, volume: 81, edition: April 2025, DOI
-
HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy
Leukemia, year: 2025, DOI
-
The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer
Molecular Cancer, year: 2025, volume: 24, edition: 1, DOI
2024
-
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma
British journal of cancer, year: 2024, volume: 131, edition: 11, DOI
-
STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma
CELL REPORTS MEDICINE, year: 2024, volume: 5, edition: 3, DOI
-
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma
Nature Communications, year: 2024, volume: 15, edition: 1, DOI
2023
-
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, year: 2023, volume: 36, edition: 1, DOI
-
Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma
LANCET HAEMATOLOGY, year: 2023, volume: 10, edition: 3, DOI
-
Patient-derived xenograft models of ALK plus ALCL reveal preclinical promise for therapy with brigatinib
British journal of haematology, year: 2023, volume: 20, edition: 5, DOI